Image For Activity Cover
Antithrombotic Therapy after Transcatheter Aortic Valve (JACC Cardiovascular Interventions August 2021)
Transcatheter aortic valve replacement (TAVR) is a treatment option for symptomatic
patients with severe aortic stenosis who are candidates for a bioprosthesis across the entire
spectrum of risk. However, TAVR carries a risk for thrombotic and bleeding events
underscoring the importance of defining the optimal adjuvant antithrombotic regimen.


JACC: Cardiovascular Interventions Editor-in-Chief

David J. Moliterno, MD, FACC

JACC: Cardiovascular Interventions CME/MOC/ECME Editor

Michael C. McDaniel, MD


Dominick J. Angiolillo, MD, PhD

Important Dates

Date of Release: August 2, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: August 1, 2022

Availability: On-Demand
Expires on Aug 01, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By